The pharmaceutical industry is building increasingly complex manufacturing networks. Products move between internal plants, CMOs, CDMOs, regions, and qualified backup sites as organizations respond to capacity constraints, new modalities, localization strategies, and geopolitical uncertainty.
But when the molecule moves, the economics move with it.
A decision that appears operational can have significant implications for pricing, capacity commitments, transfer costs, royalties, profit-sharing agreements, settlements, and ultimately product margin.
Watch our webinar on-demand and discover how leading pharmaceutical companies are rethinking manufacturing networks, not only from a supply and operations perspective, but also from a commercial and financial one.
You will learn:
- Why manufacturing flexibility and optionality are becoming strategic assets
- The hidden commercial implications of network decisions
- How agreements, pricing, and partner economics must evolve to support new operating models
- Why visibility across contracts, commitments, royalties, settlements, and margin outcomes is becoming increasingly critical
- How a connected approach to commercial orchestration can help organizations bridge the gap between manufacturing strategy and financial performance
Discover why the next competitive advantage in Life Sciences may not come from moving molecules faster, but from understanding the commercial impact of every move.
Presenter:
Alejandra Garitonandia
Manager Global Industry and LS Industry Principal at Vistex EMEA